Results 131 to 140 of about 717 (150)

Asfotase alfa: Enzyme replacement for the treatment of bone disease in hypophosphatasia

Drugs of Today, 2016
Hypophosphatasia (HPP) is a rare disease caused by loss-of-function mutations in the tissue-nonspecific alkaline phosphatase (TNAP, TNSALP) gene. HPP causes a multisystemic syndrome with a predominant bone phenotype. The clinical spectrum ranges from high lethality in early onset (
C, Hofmann, L, Seefried, F, Jakob
openaire   +2 more sources

Asfotase-alfa

Reactions Weekly, 2023
openaire   +2 more sources

Ectopic Ocular Surface Calcification in Patients With Hypophosphatasia Treated With Asfotase Alfa

Cornea, 2019
Purpose: To assess for ectopic ocular calcification in a series of patients with hypophosphatasia (HPP) treated with asfotase alfa, a recombinant tissue-nonspecific alkaline phosphatase. Methods: This is a retrospective analysis of subjects enrolled at Duke University Medical Center
Sidney M, Gospe, Cecilia, Santiago-Turla, Stephanie M, DeArmey, Thomas J, Cummings, Priya S, Kishnani, M Tariq, Bhatti   +5 more
openaire   +2 more sources

Asfotase-alfa

Reactions Weekly, 2022
openaire   +2 more sources

Asfotase-alfa

Reactions Weekly, 2021
openaire   +1 more source

Asfotase-alfa/influenza-virus-vaccine

Reactions Weekly, 2023
openaire   +1 more source

Asfotase alfa

Reactions Weekly, 2019
openaire   +1 more source

Bone healing and reactivation of remodeling under asfotase alfa therapy in adult patients with pediatric-onset hypophosphatasia

Bone, 2021
Felix N Schmidt, Ralf Oheim, Florian Barvencik   +2 more
exaly  

Spurious testosterone laboratory results in a patient taking synthetic alkaline phosphatase (asfotase alfa)

Clinical Biochemistry, 2018
Eric Rush, Whitney Goldner
exaly  

Safety and efficacy of treatment with asfotase alfa in patients with hypophosphatasia: Results from a Japanese clinical trial

Clinical Endocrinology, 2017
Tsutomu Ogata, Atsushi Watanabe, Taichi Kitaoka   +2 more
exaly